Celldex brings out the ax in wake of breast can­cer drug dis­as­ter, chop­ping a quar­ter of its staff

Celldex Ther­a­peu­tics $CLDX is re­struc­tur­ing and cut­ting back in the af­ter­math of a dis­as­trous Phase IIb read­out. The com­pa­ny — no stranger to mis­for­tune — re­port­ed late …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER